| TBX21 attenuates colorectal cancer progression via an ARHGAP29/RSK/GSK3beta dependent manner. | TBX21 attenuates colorectal cancer progression via an ARHGAP29/RSK/GSK3β dependent manner.
Jiang X, Du W, Yang C, Wang S, Li Y, Shen X, Yang X, Yao J, Du R, Zhang X, Huang Y, Shen W. | 12/1/2023 |
| RSK3 switches cell fate: from stress-induced senescence to malignant progression. | RSK3 switches cell fate: from stress-induced senescence to malignant progression.
Huna A, Flaman JM, Lodillinsky C, Zhu K, Makulyte G, Pakulska V, Coute Y, Ruisseaux C, Saintigny P, Hernandez-Vargas H, Defossez PA, Boissan M, Martin N, Bernard D., Free PMC Article | 11/30/2023 |
| mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer. | mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer.
Kumari A, Gesumaria L, Liu YJ, Hughitt VK, Zhang X, Ceribelli M, Wilson KM, Klumpp-Thomas C, Chen L, McKnight C, Itkin Z, Thomas CJ, Mock BA, Schrump DS, Chen H., Free PMC Article | 03/10/2023 |
| Multiomics analysis identifies key genes and pathways related to N6-methyladenosine RNA modification in ovarian cancer. | Multiomics analysis identifies key genes and pathways related to N6-methyladenosine RNA modification in ovarian cancer.
Xu H, Li X, Wang S, Li F, Gao J, Yan L, Zhu L. | 03/12/2022 |
| Genome-wide association study of cafe-au-lait macule number in neurofibromatosis type 1. | Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.
Sung H, Hyland PL, Pemov A, Sabourin JA, Baldwin AM, Bass S, Teshome K, Luo W, Frederick National Laboratory for Cancer Research, Widemann BC, Stewart DR, Wilson AF., Free PMC Article | 06/5/2021 |
| Elevated ribosomal protein S6 kinase A2 (RSK3) expression is responsible for BET bromodomain inhibitors (BETi) resistance. Proto-Oncogene Proteins c-jun (JunD)-dependent RSK3 transcription mediates BETi resistance. JunD/RSK3 signalling correlates to BET inhibition sensitivity. Loss of BRD4/FOXD3/miR-548d-3p axis enhances JunD/RSK3 signalling and determines BET inhibition resistance. | Enhanced JunD/RSK3 signalling due to loss of BRD4/FOXD3/miR-548d-3p axis determines BET inhibition resistance.
Tai F, Gong K, Song K, He Y, Shi J., Free PMC Article | 04/25/2020 |
| Data suggest that millisecond dynamic changes in PDZ1 domain conformation are responsible for higher affinity of scribble PDZ1 for phosphorylated ligands; oligopeptide fragments of RPS6KA2 and MCC were used as ligands in these nuclear magnetic resonance chemical shift experiments. (RPS6KA2 = ribosomal protein S6 kinase 2; MCC = mutated in colorectal cancer protein) | The Sign of Nuclear Magnetic Resonance Chemical Shift Difference as a Determinant of the Origin of Binding Selectivity: Elucidation of the Position Dependence of Phosphorylation in Ligands Binding to Scribble PDZ1.
Sundell GN, Vögeli B, Ivarsson Y, Chi CN. | 05/19/2018 |
| RSK1 and 3 but not RSK2 are down-regulated in breast tumour and are associated with disease progression. RSK may be a key component in the progression and metastasis of breast cancer. | The Clinical Implications of RSK1-3 in Human Breast Cancer.
Zhao H, Martin TA, Davies EL, Ruge F, Yu H, Zhang Y, Teng XU, Jiang WG. | 11/12/2016 |
| Data indicate that S6 kinase 2 (S6K2) can phosphorylate histone H3 at position Thr45, which may play a role during cell proliferation and/or differentiation. | S6 kinase 2 is bound to chromatin-nuclear matrix cellular fractions and is able to phosphorylate histone H3 at threonine 45 in vitro and in vivo.
Ismail HM, Hurd PJ, Khalil MI, Kouzarides T, Bannister A, Gout I. | 12/20/2014 |
| Kinome screening revealed RPS6KA2 expression, in human pancreatic cancer cells, protects against erlotinib induced apoptosis. | Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer.
Milosevic N, Kühnemuth B, Mühlberg L, Ripka S, Griesmann H, Lölkes C, Buchholz M, Aust D, Pilarsky C, Krug S, Gress T, Michl P., Free PMC Article | 09/13/2014 |
| genetic association study in Han population in China: Data suggest that SNPs in RSK3 (rs2229712) and in MEK1 (rs28730804) demonstrate gene-gene interaction that affects antidepressant drug outcome in female patients with major depressive disorder. | Kinase gene haplotypes and gene-gene interactions in the Ras-Raf-MAPK signaling pathway: association with antidepressant remission.
Wang CJ, Zhang ZJ, Xu Z, Shi YY, Pu MJ, Zheng Z, Wang XZ, Zhang YM, Li LJ. | 03/15/2014 |
| Overexpression of RSK3 or RSK4 supports tumor cell proliferation upon PI3K inhibition both in vitro and in vivo therby contributing to drug resistance. | RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.
Serra V, Eichhorn PJ, García-García C, Ibrahim YH, Prudkin L, Sánchez G, Rodríguez O, Antón P, Parra JL, Marlow S, Scaltriti M, Pérez-Garcia J, Prat A, Arribas J, Hahn WC, Kim SY, Baselga J., Free PMC Article | 08/3/2013 |
| p90RSK2 is dispensable for BCR-ABL-induced myeloid leukemia, but may be required for pathogenesis and lineage determination in FLT3-internal tandem duplication-induced hematopoietic transformation. | p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.
Elf S, Blevins D, Jin L, Chung TW, Williams IR, Lee BH, Lin JX, Leonard WJ, Taunton J, Khoury HJ, Kang S., Free PMC Article | 09/10/2011 |
| Data show that genetic variation in RPS6KA1, RPS6KA2, and PRS6KB2 were associated with risk of developing colon cancer while only genetic variation in RPS6KA2 was associated with altering risk of rectal cancer. | Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer.
Slattery ML, Lundgreen A, Herrick JS, Wolff RK, Slattery ML, Lundgreen A, Herrick JS, Wolff RK., Free PMC Articles: PMC3038588, PMC3038588 | 03/5/2011 |
| Observational study of gene-disease association. (HuGE Navigator) | Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer.
Slattery ML, Lundgreen A, Herrick JS, Wolff RK, Slattery ML, Lundgreen A, Herrick JS, Wolff RK., Free PMC Articles: PMC3038588, PMC3038588 | 12/5/2010 |
| Clinical trial of gene-disease association and gene-environment interaction. (HuGE Navigator) | Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR., Free PMC Article | 06/30/2010 |
| p90Rsk-mediated modulation of Hdm2 nuclear is linked to cytoplasmic shuttling with the diminished ability of p53 to regulate cell cycle checkpoints that ultimately leads to transformation | Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells.
Jackson MW, Patt LE, LaRusch GA, Donner DB, Stark GR, Mayo LD. | 01/21/2010 |
| there is a functional link between S6K1 II and CK2 signaling, which involves the regulation of S6K1 II nuclear export by CK2-mediated phosphorylation of Ser-17 | Nuclear export of S6K1 II is regulated by protein kinase CK2 phosphorylation at Ser-17.
Panasyuk G, Nemazanyy I, Zhyvoloup A, Bretner M, Litchfield DW, Filonenko V, Gout IT. | 01/21/2010 |
| The accumulation of S6K2 in the nuclei of cancer cells and the correlation with the expression of PCNA and Ki-67 suggest the involvement of S6K2 in the regulation of malignant growth | Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer.
Lyzogubov V, Khozhaenko Y, Usenko V, Antonjuk S, Ovcharenko G, Tikhonkova I, Filonenko V. | 01/21/2010 |
| Characterization of the terminal domain as a protein kinase | Characterization of the p90 ribosomal S6 kinase 2 carboxyl-terminal domain as a protein kinase.
Chrestensen CA, Sturgill TW. | 01/21/2010 |
| chronic activation CREB and p90RSK in the epileptic hippocampus may be closely associated with the histopathological changes of Ammon's horn sclerosis | Chronic activation of CREB and p90RSK in human epileptic hippocampus.
Park SA, Kim TS, Choi KS, Park HJ, Heo K, Lee BI. | 01/21/2010 |
| overexpressed in breast tumors | Immunohistochemical analysis of S6K1 and S6K2 expression in human breast tumors.
Savinska LO, Lyzogubov VV, Usenko VS, Ovcharenko GV, Gorbenko ON, Rodnin MV, Vudmaska MI, Pogribniy PV, Kyyamova RG, Panasyuk GG, Nemazanyy IO, Malets MS, Palchevskyy SS, Gout IT, Filonenko VV. | 01/21/2010 |
| The large C-terminal domain of ERK5 is not required for binding or activation of RSK by ERK5. | The MAP kinase ERK5 binds to and phosphorylates p90 RSK.
Ranganathan A, Pearson GW, Chrestensen CA, Sturgill TW, Cobb MH. | 01/21/2010 |
| The above results suggest that RPS6KA2 is a putative tumour suppressor gene to explain allele loss at 6q27. | RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
Bignone PA, Lee KY, Liu Y, Emilion G, Finch J, Soosay AE, Charnock FM, Beck S, Dunham I, Mungall AJ, Ganesan TS. | 01/21/2010 |